ADIPOQ and atrial fibrillation: Pooled results with a random-effect model showed that higher baseline circulating adiponectin was significantly associated with higher risk of new-onset AF during follow-up (HR: 1.17, 95% CI: 1.08–1.27, P<0.001; Figure 2) with considerable heterogeneity (P for Cochrane’s Q test =0.07, I2 = 52%).